These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10176313)

  • 1. Price regulation of pharmaceuticals in Canada.
    Anis AH; Wen Q
    J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals.
    Shajarizadeh A; Hollis A
    Health Econ; 2015 Aug; 24(8):966-77. PubMed ID: 24990225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Canadian Patented Medicine Prices Review Board. New rules and new status.
    Shulman SR
    Pharmacoeconomics; 1994; 6 Suppl 1():71-9. PubMed ID: 10155589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An empirical analysis of the multimarket contact theory in pharmaceutical markets.
    Coronado J; Jiménez-Martín S; Marín PL
    Eur J Health Econ; 2014 Jul; 15(6):623-43. PubMed ID: 23818281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
    Boonen LH; van der Geest SA; Schut FT; Varkevisser M
    Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Price regulation in the pharmaceutical industry: prescription or placebo?
    Abbott TA
    J Health Econ; 1995 Dec; 14(5):551-65. PubMed ID: 10156501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995-2007.
    Puig-Junoy J; López-Valcárcel BG
    Health Policy; 2014 Jun; 116(2-3):170-81. PubMed ID: 24641938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices.
    Lexchin J
    CMAJ; 2006 Apr; 174(8):1120-1. PubMed ID: 16606961
    [No Abstract]   [Full Text] [Related]  

  • 18. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problems in the regulatory policy of the drug market.
    Miziara NM; Coutinho DR
    Rev Saude Publica; 2015; 49():35. PubMed ID: 26083945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.